Acadia Pharmaceuticals Inc [ACAD] stock prices are up 14.31% to $16.93 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ACAD shares have gain 16.20% over the last week, with a monthly amount glided 20.07%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Acadia Pharmaceuticals Inc [NASDAQ: ACAD] stock has seen the most recent analyst activity on February 11, 2025, when Deutsche Bank initiated its Hold rating and assigned the stock a price target of $22. Previously, Guggenheim downgraded its rating to Neutral on January 03, 2025, and dropped its price target to $20. Morgan Stanley downgraded its rating to a Equal-Weight and decreased its price target to $20 on August 07, 2024. BMO Capital Markets initiated its recommendation with a Outperform and recommended $31 as its price target on June 27, 2024. Needham reiterated a Buy rating for this stock on March 12, 2024, and downed its price target to $32. In a note dated March 12, 2024, Mizuho downgraded an Neutral rating on this stock and revised its target price from $39 to $25.
The stock price of Acadia Pharmaceuticals Inc [ACAD] has been fluctuating between $13.40 and $20.68 over the past year. Currently, Wall Street analysts expect the stock to reach $21 within the next 12 months. Acadia Pharmaceuticals Inc [NASDAQ: ACAD] shares were valued at $16.93 at the most recent close of the market. An investor can expect a potential return of 24.04% based on the average ACAD price forecast.
Analyzing the ACAD fundamentals
The Acadia Pharmaceuticals Inc [NASDAQ:ACAD] reported sales of 996.28M for trailing twelve months, representing a surge of 18.70%. Gross Profit Margin for this corporation currently stands at 0.91% with Operating Profit Margin at 0.24%, Pretax Profit Margin comes in at 0.27%, and Net Profit Margin reading is 0.24%. To continue investigating profitability, this company’s Return on Assets is posted at 0.19, Equity is 0.4 and Total Capital is 0.29. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 15.33 points at the first support level, and at 13.74 for the second support level. However, for the 1st resistance point, the stock is sitting at 17.87, and for the 2nd resistance point, it is at 18.82.
Ratios To Look Out For
It’s worth pointing out that Acadia Pharmaceuticals Inc [NASDAQ:ACAD]’s Current Ratio is 2.88. Also, the Quick Ratio is 2.80, while the Cash Ratio stands at 0.81. Considering the valuation of this stock, the price to sales ratio is 2.84, the price to book ratio is 3.85 and price to earnings (TTM) ratio is 12.35.
Transactions by insiders
Recent insider trading involved Kihara James, PRINCIPAL ACCOUNTING OFFICER, that happened on May 02 ’25 when 1327.0 shares were sold. EVP, CHIEF FINANCIAL OFFICER, Schneyer Mark C. completed a deal on May 02 ’25 to sell 3498.0 shares. Meanwhile, EVP, CHIEF FINANCIAL OFFICER Schneyer Mark C. sold 2708.0 shares on Apr 08 ’25.
